COGT Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of 18.15%. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Merck & Co., Inc.'s return on equity of 36.76%.

Cogent Biosciences, Inc. has a consensus price target of $53.83, signalling upside risk potential of 38.57%. On the other hand Merck & Co., Inc. has an analysts' consensus of $127.18 which suggests that it could grow by 2.22%. Given that Cogent Biosciences, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Merck & Co., Inc..

Cogent Biosciences, Inc. has a beta of 0.468, which suggesting that the stock is 53.231% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.269, suggesting its less volatile than the S&P 500 by 73.077%.

Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.65% to investors and pays a quarterly dividend of $0.85 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Cogent Biosciences, Inc.'s net income of -$102.5M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 17.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 4.78x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of --. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Cogent Biosciences, Inc. has a consensus price target of $53.83, signalling upside risk potential of 38.57%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $46.09 which suggests that it could grow by 90.46%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Cogent Biosciences, Inc..

Cogent Biosciences, Inc. has a beta of 0.468, which suggesting that the stock is 53.231% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.926, suggesting its more volatile than the S&P 500 by 92.554%.

Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$102.5M is lower than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of --. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Revolution Medicines, Inc.'s return on equity of -59.94%.

Cogent Biosciences, Inc. has a consensus price target of $53.83, signalling upside risk potential of 38.57%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $130.05 which suggests that it could grow by 27.32%. Given that Cogent Biosciences, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Revolution Medicines, Inc..

Cogent Biosciences, Inc. has a beta of 0.468, which suggesting that the stock is 53.231% less volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.875%.

Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Revolution Medicines, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$102.5M is higher than Revolution Medicines, Inc.'s net income of -$364.9M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -93.07%. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Sarepta Therapeutics, Inc.'s return on equity of -64.94%.

Cogent Biosciences, Inc. has a consensus price target of $53.83, signalling upside risk potential of 38.57%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.04 which suggests that it could grow by 25.56%. Given that Cogent Biosciences, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Sarepta Therapeutics, Inc..

Cogent Biosciences, Inc. has a beta of 0.468, which suggesting that the stock is 53.231% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.424, suggesting its less volatile than the S&P 500 by 57.628%.

Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $442.9M. Cogent Biosciences, Inc.'s net income of -$102.5M is higher than Sarepta Therapeutics, Inc.'s net income of -$412.2M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 0.78x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.